Glaukos Corp (GKOS)
$142.89 $10.77 (7.90%) 4:38 PM 12/11/24
NYSE | $USD | Medical DevicesStock Data
-
Market Cap
$7.73B -
Day's Range
$140.50 - $147.65 -
Volume
510,068 -
52 Week Low / High
$59.58 - $146.86 -
PE Ratio
- -
PEG Ratio
1.64 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 6
- Strong Buy
- 3
- Buy
- 4
- Hold
- 0
- Sell
- 0
- Strong Sell
- $85.00
- Target Price
Company News
-
Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...
-
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024
Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...
-
Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...
-
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024
Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...
-
Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...
-
Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...
-
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024
ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...
-
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024
ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...
-
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024
Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...
-
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024
ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...
-
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...
-
Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...
-
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024
ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...
-
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024
Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...
-
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024
Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...
-
Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...
-
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024
Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...
-
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...
-
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...
-
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...
-
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024
Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...
-
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...
-
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024
ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...
-
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...
-
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...
-
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024
ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...
-
Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...
-
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...
-
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024
ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...
-
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...
-
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...
-
Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the...
-
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...
-
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting — Oct 14th, 2024
ALISO VIEJO, Calif., October 14, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will...
-
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...
-
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...
-
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...
-
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024
Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...
-
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 — Oct 9th, 2024
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., October 09, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and reti...
-
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? — Oct 3rd, 2024
Glaukos Corporation GKOS has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportuniti...
-
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now — Oct 8th, 2024
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 59% year to date compared with the industry’s 5.3% growth. Th...
Portfolio
Comprised of 1 portfolios